What is the Medicare GLP-1 Bridge program?
On April 12, 2026, CMS announced the Medicare GLP-1 Bridge demonstration program — the first formal Medicare coverage for GLP-1 medications used for chronic weight management. Until now, Medicare Part D has explicitly excluded weight-loss drugs by statute (the Medicare Modernization Act of 2003).
The Bridge is a time-limited demonstration: it begins July 1, 2026 and runs through December 31, 2027. After that, CMS will evaluate outcomes and decide whether to pursue permanent coverage via the BALANCE model or new legislation.
Who qualifies for the Bridge program
You qualify if you are enrolled in Medicare Part D and meet ONE of these clinical criteria: (1) BMI ≥30, regardless of comorbidities, OR (2) BMI ≥27 with at least one weight-related condition — hypertension, type 2 diabetes (without HbA1c above a threshold), dyslipidemia, sleep apnea, or established cardiovascular disease.
Prior authorization is required. Your prescriber must submit BMI documentation, the qualifying condition's clinical record, and confirmation that you've attempted lifestyle interventions (though this last requirement is being interpreted loosely in CMS guidance).
Which medications are covered
Bridge covers all FDA-approved GLP-1 medications with active obesity indications: Foundayo (orforglipron), Wegovy (injectable and oral), Zepbound (KwikPen + auto-injector), and Mounjaro (for patients with diabetes comorbidity). Saxenda and Contrave are also covered but rarely prescribed.
Notably excluded: compounded semaglutide and compounded tirzepatide — Bridge only covers FDA-approved branded formulations.
How to enroll
Step 1: confirm you have Medicare Part D enrollment. The Bridge runs through Part D, not Original Medicare or Part B.
Step 2: book an appointment with a prescriber (PCP, endocrinologist, or telehealth provider that accepts Medicare). Bring documentation of your BMI and any qualifying conditions.
Step 3: prescriber submits the Bridge prior auth packet to your Part D plan. CMS estimates 3-5 business days for processing.
Step 4: fill at any pharmacy that accepts your Part D plan. Mail-order pharmacies (Express Scripts Home Delivery, CVS Caremark Mail) generally have the lowest out-of-pocket on the $50 copay structure.
What about state Medicaid coverage?
Separately from Medicare, 13 state Medicaid programs cover GLP-1s for obesity as of mid-2026 — up from 9 in 2024. The list includes Virginia, Massachusetts, Pennsylvania, North Carolina, California, Minnesota, Connecticut, Delaware, Kansas, New Hampshire, Rhode Island, Vermont, and Wisconsin.
Four states (Iowa, Texas, Florida, and Georgia) eliminated GLP-1 coverage from their Medicaid programs in 2025 citing budget constraints. If you live in one of these states, the Bridge program (Medicare) is the only public-coverage path; state-by-state pricing matters more than ever.
Frequently asked questions
- When does Medicare start covering Ozempic and Wegovy for weight loss?
- July 1, 2026 via the Medicare GLP-1 Bridge demonstration program. Eligible beneficiaries pay a $50/month copay through December 31, 2027.
- Does Medicare cover Ozempic for diabetes?
- Yes — Ozempic has been covered under Medicare Part D for type 2 diabetes since FDA approval. The Bridge program is specifically for weight-loss indications (Wegovy, Zepbound, Foundayo, oral Wegovy).
- What is the BMI requirement for Medicare GLP-1 coverage?
- BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, sleep apnea, dyslipidemia, type 2 diabetes, or cardiovascular disease).
- Does the Bridge program cover compounded semaglutide?
- No. Only FDA-approved branded medications are covered. Compounded formulations from 503A pharmacies are not included.
- What happens after the Bridge program ends in 2027?
- Uncertain. CMS will evaluate the demonstration and decide whether to pursue permanent coverage through the BALANCE model (a separate proposed pathway), seek congressional action, or let coverage lapse. Plan with a 2-year horizon.
Disclosure: Glpverdict is affiliate-funded but editorially independent. Some links above are sponsored — we may earn a commission if you sign up with a partner provider. This does not affect our editorial rankings or medical review.
